The U.S. Food and Drug Administration (FDA) has approved Cobenfy, a groundbreaking new drug for schizophrenia that promises to revolutionize treatment with its novel mechanism, the first of its kind in decades.
Schizophrenia is a serious and disabling mental health condition that affects the way a person thinks, feels, and behaves. About 1% of Americans are affected by schizophrenia, making it one of the 15 leading causes of disability worldwide.
